Verrica Pharmaceuticals Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company generated total revenue of $14.3 million for the quarter, a substantial increase from a loss of $1.8 million in the same period last year. This growth was driven by product revenue of $3.6 million, compared to a negative $1.9 million in the prior year, and license and collaboration revenue of $10.7 million, up from just $0.1 million. For the nine months ended September 30, 2025, total revenue reached $30.5 million, compared to $7.2 million in the same period of 2024.
Operating expenses for the third quarter decreased to $12.7 million from $18.9 million year-over-year, primarily due to reduced selling, general, and administrative costs, which fell from $16.1 million to $9.4 million. The company reported a net loss of $0.3 million for the quarter, a significant improvement from a net loss of $22.9 million in the prior year. For the nine-month period, the net loss was $9.8 million, compared to $60.4 million in the same period of 2024, indicating a positive trend in financial performance.
Strategically, Verrica has made notable advancements, including the FDA approval of its product YCANTH (VP-102) for the treatment of molluscum contagiosum in July 2023. The company has also entered into a collaboration with Torii Pharmaceutical Co., Ltd., which has resulted in milestone payments totaling $18 million in 2025. The company plans to expand its sales force from 36 to 50 representatives and launch a non-dispensing pharmacy, YCANTH Rx, to streamline prescription processes.
As of September 30, 2025, Verrica reported cash and cash equivalents of $21.1 million, down from $46.3 million at the end of 2024. The company has incurred substantial operating losses since its inception, with an accumulated deficit of $316.8 million. The filing indicates that there is substantial doubt regarding the company's ability to continue as a going concern within the next year, primarily due to its ongoing financial obligations and the need for additional funding. The company plans to address these challenges through equity offerings, debt financing, and strategic partnerships.
About Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals develops dermatology treatments, including FDA-approved YCANTH (VP-102) for molluscum contagiosum, a contagious skin disease. The company focuses on clinician-administered therapies for high unmet needs, with pipeline products targeting common warts and dermatologic cancers like basal cell carcinoma. Its business model emphasizes innovative formulations, strategic licensing, and commercialization through specialized sales, targeting healthcare providers and patients worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.